JP2016094451A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016094451A5 JP2016094451A5 JP2015246589A JP2015246589A JP2016094451A5 JP 2016094451 A5 JP2016094451 A5 JP 2016094451A5 JP 2015246589 A JP2015246589 A JP 2015246589A JP 2015246589 A JP2015246589 A JP 2015246589A JP 2016094451 A5 JP2016094451 A5 JP 2016094451A5
- Authority
- JP
- Japan
- Prior art keywords
- nmol
- hour
- composition
- naglu
- fold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35885710P | 2010-06-25 | 2010-06-25 | |
| US61/358,857 | 2010-06-25 | ||
| US36078610P | 2010-07-01 | 2010-07-01 | |
| US61/360,786 | 2010-07-01 | ||
| US38786210P | 2010-09-29 | 2010-09-29 | |
| US61/387,862 | 2010-09-29 | ||
| US201161435710P | 2011-01-24 | 2011-01-24 | |
| US61/435,710 | 2011-01-24 | ||
| US201161442115P | 2011-02-11 | 2011-02-11 | |
| US61/442,115 | 2011-02-11 | ||
| US201161476210P | 2011-04-15 | 2011-04-15 | |
| US61/476,210 | 2011-04-15 | ||
| US201161495268P | 2011-06-09 | 2011-06-09 | |
| US61/495,268 | 2011-06-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516847A Division JP6063380B2 (ja) | 2010-06-25 | 2011-06-25 | サンフィリポ症候群ｂ型の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016094451A JP2016094451A (ja) | 2016-05-26 |
| JP2016094451A5 true JP2016094451A5 (https=) | 2016-09-08 |
Family
ID=45352777
Family Applications (22)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236539A Active JP6250616B2 (ja) | 2010-06-25 | 2015-12-03 | 治療薬のｃｎｓ送達 |
| JP2015246589A Pending JP2016094451A (ja) | 2010-06-25 | 2015-12-17 | サンフィリポ症候群ｂ型の処置 |
| JP2015246244A Active JP6285409B2 (ja) | 2010-06-25 | 2015-12-17 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2015246258A Withdrawn JP2016040335A (ja) | 2010-06-25 | 2015-12-17 | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2015246952A Active JP6346162B2 (ja) | 2010-06-25 | 2015-12-18 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2017177784A Active JP6466538B2 (ja) | 2010-06-25 | 2017-09-15 | 治療薬のｃｎｓ送達 |
| JP2017194508A Active JP6522073B2 (ja) | 2010-06-25 | 2017-10-04 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2017194348A Active JP6522072B2 (ja) | 2010-06-25 | 2017-10-04 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2018192589A Active JP6797876B2 (ja) | 2010-06-25 | 2018-10-11 | 治療薬のｃｎｓ送達 |
| JP2018226358A Active JP6898909B2 (ja) | 2010-06-25 | 2018-12-03 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2018227369A Active JP6938456B2 (ja) | 2010-06-25 | 2018-12-04 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2020000930A Withdrawn JP2020079244A (ja) | 2010-06-25 | 2020-01-07 | 治療薬のｃｎｓ送達 |
| JP2020023620A Pending JP2020079297A (ja) | 2010-06-25 | 2020-02-14 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2020024183A Pending JP2020079298A (ja) | 2010-06-25 | 2020-02-17 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2021115560A Active JP7448507B2 (ja) | 2010-06-25 | 2021-07-13 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2021115564A Active JP7087175B2 (ja) | 2010-06-25 | 2021-07-13 | 治療薬のｃｎｓ送達 |
| JP2021133184A Active JP7591476B2 (ja) | 2010-06-25 | 2021-08-18 | イズロン酸－２－スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2021196898A Active JP7359827B2 (ja) | 2010-06-25 | 2021-12-03 | 治療薬のｃｎｓ送達 |
| JP2023014814A Active JP7543459B2 (ja) | 2010-06-25 | 2023-02-02 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2023024170A Pending JP2023062114A (ja) | 2010-06-25 | 2023-02-20 | イズロン酸－２－スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2023078673A Pending JP2023099216A (ja) | 2010-06-25 | 2023-05-11 | 治療薬のｃｎｓ送達 |
| JP2024069806A Ceased JP2024097029A (ja) | 2010-06-25 | 2024-04-23 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236539A Active JP6250616B2 (ja) | 2010-06-25 | 2015-12-03 | 治療薬のｃｎｓ送達 |
Family Applications After (20)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015246244A Active JP6285409B2 (ja) | 2010-06-25 | 2015-12-17 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2015246258A Withdrawn JP2016040335A (ja) | 2010-06-25 | 2015-12-17 | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2015246952A Active JP6346162B2 (ja) | 2010-06-25 | 2015-12-18 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2017177784A Active JP6466538B2 (ja) | 2010-06-25 | 2017-09-15 | 治療薬のｃｎｓ送達 |
| JP2017194508A Active JP6522073B2 (ja) | 2010-06-25 | 2017-10-04 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2017194348A Active JP6522072B2 (ja) | 2010-06-25 | 2017-10-04 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2018192589A Active JP6797876B2 (ja) | 2010-06-25 | 2018-10-11 | 治療薬のｃｎｓ送達 |
| JP2018226358A Active JP6898909B2 (ja) | 2010-06-25 | 2018-12-03 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2018227369A Active JP6938456B2 (ja) | 2010-06-25 | 2018-12-04 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2020000930A Withdrawn JP2020079244A (ja) | 2010-06-25 | 2020-01-07 | 治療薬のｃｎｓ送達 |
| JP2020023620A Pending JP2020079297A (ja) | 2010-06-25 | 2020-02-14 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2020024183A Pending JP2020079298A (ja) | 2010-06-25 | 2020-02-17 | イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2021115560A Active JP7448507B2 (ja) | 2010-06-25 | 2021-07-13 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2021115564A Active JP7087175B2 (ja) | 2010-06-25 | 2021-07-13 | 治療薬のｃｎｓ送達 |
| JP2021133184A Active JP7591476B2 (ja) | 2010-06-25 | 2021-08-18 | イズロン酸－２－スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2021196898A Active JP7359827B2 (ja) | 2010-06-25 | 2021-12-03 | 治療薬のｃｎｓ送達 |
| JP2023014814A Active JP7543459B2 (ja) | 2010-06-25 | 2023-02-02 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
| JP2023024170A Pending JP2023062114A (ja) | 2010-06-25 | 2023-02-20 | イズロン酸－２－スルファターゼのｃｎｓ送達のための方法および組成物 |
| JP2023078673A Pending JP2023099216A (ja) | 2010-06-25 | 2023-05-11 | 治療薬のｃｎｓ送達 |
| JP2024069806A Ceased JP2024097029A (ja) | 2010-06-25 | 2024-04-23 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
Country Status (24)
| Country | Link |
|---|---|
| US (17) | US9814764B2 (https=) |
| JP (22) | JP6250616B2 (https=) |
| CN (4) | CN104857504A (https=) |
| AR (6) | AR082025A1 (https=) |
| BR (1) | BR112012033214B1 (https=) |
| CA (1) | CA3171308A1 (https=) |
| CL (7) | CL2012003656A1 (https=) |
| DK (3) | DK3626258T3 (https=) |
| ES (3) | ES2895655T3 (https=) |
| HK (1) | HK1214149A1 (https=) |
| HR (3) | HRP20211520T1 (https=) |
| HU (6) | HUE056884T2 (https=) |
| LT (3) | LT3626258T (https=) |
| MX (1) | MX354776B (https=) |
| NZ (2) | NZ702803A (https=) |
| PE (8) | PE20130637A1 (https=) |
| PL (1) | PL2588130T3 (https=) |
| PT (6) | PT3103469T (https=) |
| RS (3) | RS61683B1 (https=) |
| RU (1) | RU2761342C2 (https=) |
| SI (3) | SI3103469T1 (https=) |
| SM (1) | SMT201600385B (https=) |
| TW (9) | TWI698252B (https=) |
| UA (3) | UA125743C2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759297B2 (en) | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
| AU2008282496B2 (en) | 2007-07-27 | 2013-04-04 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-iduronidase activity in the CNS |
| EP2485761B1 (en) | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| PT3103469T (pt) | 2010-06-25 | 2021-03-04 | Shire Human Genetic Therapies | Administração de agentes terapêuticos no snc |
| LT2588130T (lt) | 2010-06-25 | 2016-12-12 | Shire Human Genetic Therapies, Inc. | Terapinės priemonės pristatymas cns |
| JP6073783B2 (ja) | 2010-06-25 | 2017-02-01 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
| HRP20191923T1 (hr) | 2010-06-25 | 2020-01-10 | Shire Human Genetic Therapies, Inc. | Postupci i sastavi za isporuku arilsulfataze a u cns |
| US20220133863A1 (en) * | 2010-06-25 | 2022-05-05 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
| AU2012346448B2 (en) | 2011-12-02 | 2017-09-14 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
| US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| US9682129B2 (en) * | 2011-12-23 | 2017-06-20 | Shire Human Genetic Therapies, Inc. | Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase |
| CN115120746A (zh) * | 2013-05-15 | 2022-09-30 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
| US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| CA2985235A1 (en) | 2015-05-07 | 2016-11-10 | Shire Human Genetic Therapies, Inc. | Glucocerebrosidase gene therapy for parkinson's disease |
| PL3397270T3 (pl) * | 2015-12-30 | 2024-08-19 | Green Cross Corporation | Kompozycje do zastosowania w leczeniu zespołu huntera |
| MX2018010196A (es) * | 2016-02-24 | 2018-11-19 | Biomarin Pharm Inc | Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas. |
| SG10201912761UA (en) | 2016-04-15 | 2020-02-27 | The Trustees Of The Univ Of Pennsyvania | Gene therapy for treating mucopolysaccharidosis type ii |
| KR102883778B1 (ko) | 2017-09-22 | 2025-11-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Ii형 점액다당류증의 치료를 위한 유전자 요법 |
| EP3760220B1 (en) * | 2018-02-28 | 2025-02-19 | Seikagaku Corporation | A package comprising lyophilized chondroitinase abc and method for manufacturing the same |
| JP7321142B2 (ja) | 2018-02-28 | 2023-08-04 | 生化学工業株式会社 | 医薬組成物、包装体及びその製造方法 |
| CN108534695A (zh) * | 2018-05-04 | 2018-09-14 | 无锡恩特卫自动化检测设备有限公司 | 一种基于机器视觉系统的瓶塞漏酒检测方法及装置 |
| KR102671857B1 (ko) * | 2018-05-30 | 2024-06-04 | 주식회사 녹십자 | 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물 |
| US11738068B2 (en) | 2018-06-25 | 2023-08-29 | Jcr Pharmaceuticals Co., Ltd. | Protein-containing aqueous liquid formulation |
| JP7253770B2 (ja) * | 2019-01-18 | 2023-04-07 | 株式会社大一商会 | 遊技機 |
| JP7253771B2 (ja) * | 2019-01-18 | 2023-04-07 | 株式会社大一商会 | 遊技機 |
| EP4229192A1 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| CN113283465B (zh) * | 2021-04-02 | 2022-04-29 | 电子科技大学 | 一种弥散张量成像数据分析方法及装置 |
| WO2022271466A1 (en) | 2021-06-21 | 2022-12-29 | Juvena Therapeutics, Inc. | Regenerative polypeptides and uses thereof |
| CN115116623A (zh) * | 2022-06-28 | 2022-09-27 | 深圳市儿童医院 | 一种基于icd疾病编码的抗菌药物使用指标评价方法、终端 |
| WO2025054521A1 (en) * | 2023-09-07 | 2025-03-13 | Juvena Therapeutics, Inc. | Igf2 fusion protein formulations and therapeutic uses thereof |
| WO2025075929A1 (en) * | 2023-10-02 | 2025-04-10 | Neurona Therapeutics Inc. | Methods of treating seizure activity |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133001A (en) * | 1959-11-26 | 1964-05-12 | Muset Pedro Puig | Stabilization of enzymes |
| US4743265A (en) | 1986-04-23 | 1988-05-10 | Dij Catheter Corp | Articulated catheter placement device |
| US5222982A (en) | 1991-02-11 | 1993-06-29 | Ommaya Ayub K | Spinal fluid driven artificial organ |
| JP3946246B2 (ja) * | 1993-02-02 | 2007-07-18 | ゾーマ・コーポレイション | 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物 |
| US5863782A (en) | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| AUPN674895A0 (en) | 1995-11-23 | 1995-12-14 | Women's And Children's Hospital | Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same |
| US6063378A (en) | 1997-08-22 | 2000-05-16 | Seikagaku Corporation | Therapeutic agent for herniated intervertebral disc |
| ES2312222T3 (es) | 1998-12-07 | 2009-02-16 | Genzyme Corporation | Tratamiento de la enfermedad de pompe. |
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| US6368315B1 (en) | 1999-06-23 | 2002-04-09 | Durect Corporation | Composite drug delivery catheter |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| US20020099025A1 (en) * | 1999-12-30 | 2002-07-25 | Heywood James A. | Treatment of neurological disorders |
| US6866844B2 (en) * | 2002-11-07 | 2005-03-15 | Biomarin Pharmaceutical Inc. | Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme |
| US20040005309A1 (en) | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| WO2002087510A2 (en) | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US20030040479A1 (en) | 2001-07-02 | 2003-02-27 | Omeros Corporation | Rotational intrathecal analgesia method and device |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| AU2002347910A1 (en) | 2001-10-16 | 2003-04-28 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| US20030181426A1 (en) | 2002-02-11 | 2003-09-25 | Eisenach James C. | Compositions and methods for treating pain using cyclooxygenase-1 inhibitors |
| DK1503788T3 (da) | 2002-04-25 | 2011-10-17 | Shire Human Genetic Therapies | Behandling af alpha-galactosidase A-deficiens |
| AU2003299471A1 (en) | 2002-05-07 | 2004-05-13 | Kai Kroll | Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
| EP1514106A4 (en) | 2002-05-29 | 2007-05-09 | Zystor Therapeutics Inc | TARGETED THERAPEUTIC PROTEINS |
| EP1426069A1 (en) | 2002-12-02 | 2004-06-09 | Diana Evelyn Miller | Drug delivery system |
| ES2371913T3 (es) | 2003-01-22 | 2012-01-11 | Duke University | Constructos mejorados para expresar polipéptidos lisosomales. |
| EP2857036B1 (en) | 2003-01-31 | 2016-12-21 | Mount Sinai School of Medicine of New York University | Combination therapy for treating protein deficiency disorders |
| US8026209B2 (en) | 2003-02-10 | 2011-09-27 | Bbb Holding B.V. | Methods and compositions for targeting agents into and across the blood-barrier and other endothelial cell microvascular barriers |
| CN1788017B (zh) * | 2003-02-10 | 2013-04-24 | to-BBB控股股份有限公司 | 炎症状态下在血脑屏障中差异表达的核酸 |
| EP1638605B1 (en) | 2003-06-20 | 2014-01-08 | Raptor Pharmaceutical, Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| EP1713904B1 (en) | 2004-01-30 | 2016-06-29 | Shire Pharmaceuticals Ireland Limited | Production and purification of recombinant arylsulfatase a |
| WO2005074888A2 (en) | 2004-02-03 | 2005-08-18 | Biodelivery Sciences International, Inc. | Replacement enzyme cochleates |
| US20080014188A1 (en) | 2004-02-06 | 2008-01-17 | Zankel Todd C | Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof |
| CA2553955C (en) | 2004-02-10 | 2012-08-28 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
| US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| UA11577U (en) | 2004-04-21 | 2006-01-16 | Academician A P Romodanov Inst | Device for intrathecal drug administration into spinal canal |
| RU2006144851A (ru) | 2004-06-15 | 2008-06-20 | Бакстер Интернэшнл Инк. (Us) | Применение терапевтических средств ex-vivo в виде твердых микрочастиц |
| US7736866B2 (en) * | 2004-08-11 | 2010-06-15 | Ciba Corporation | Enzyme-based time temperature indicator |
| IL165334A0 (en) * | 2004-11-22 | 2006-01-15 | Mediwound Ltd | Debriding composition from bromelain and methods of producing same |
| US20090297592A1 (en) * | 2005-05-11 | 2009-12-03 | Jcr Pharmaceuticals Co., Ltd. | Lipid Vesicle Composition |
| AU2006254796B2 (en) | 2005-06-08 | 2012-08-16 | Amicus Therapeutics, Inc. | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
| AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| HUE040490T2 (hu) | 2006-02-09 | 2019-03-28 | Genzyme Corp | Lassú intraventrikuláris szállítás |
| HUE042402T2 (hu) | 2006-04-04 | 2019-06-28 | Chiesi Farm Spa | Eljárás polipeptid töményítésére |
| CN101410408A (zh) * | 2006-04-04 | 2009-04-15 | 希尔制药爱尔兰有限责任公司 | 用于浓缩多肽的方法 |
| GB0611463D0 (en) | 2006-06-09 | 2006-07-19 | Novartis Ag | Organic compounds |
| US20080076120A1 (en) | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
| WO2008070769A1 (en) * | 2006-12-06 | 2008-06-12 | Medtronic, Inc. | Intrathecal catheter |
| CA2680189A1 (en) | 2007-03-06 | 2008-09-12 | Saint Louis University | Modified enzyme and treatment method |
| US20110059508A1 (en) | 2007-06-29 | 2011-03-10 | National University Corporation Nagoya University | Improving agent for dysfunction due to neuropathy and rho kinase activation inhibitor |
| WO2009017005A1 (ja) | 2007-07-27 | 2009-02-05 | Sharp Kabushiki Kaisha | 移動局装置、基地局装置、通信システム及びプログラム |
| JP2010536341A (ja) | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| WO2009062348A1 (en) * | 2007-11-14 | 2009-05-22 | Institute Of Microbiology, Chinese Academy Of Sciences | Methods for inhibiting influenza virus infection and their drugs |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| US7722865B2 (en) * | 2008-01-18 | 2010-05-25 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| CA2711590C (en) | 2008-01-18 | 2021-03-23 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| TW200936156A (en) * | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| WO2009131698A2 (en) | 2008-04-23 | 2009-10-29 | Iowa State University Research Foundation, Inc. | PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF |
| JP5627571B2 (ja) | 2008-05-07 | 2014-11-19 | バイオマリン ファーマシューティカル インコーポレイテッド | リソソーム標的化ペプチドおよびその使用 |
| US8436489B2 (en) | 2009-06-29 | 2013-05-07 | Lightsail Energy, Inc. | Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange |
| LT2588130T (lt) | 2010-06-25 | 2016-12-12 | Shire Human Genetic Therapies, Inc. | Terapinės priemonės pristatymas cns |
| PT3103469T (pt) | 2010-06-25 | 2021-03-04 | Shire Human Genetic Therapies | Administração de agentes terapêuticos no snc |
| US20110318324A1 (en) | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Methods and compositions for cns delivery of b-galactocerebrosidase |
| AU2011270672B2 (en) | 2010-06-25 | 2017-01-12 | Shire Human Genetic Therapies, Inc. | Treatment of Sanfilippo Syndrome type B |
| KR20230159646A (ko) | 2010-06-25 | 2023-11-21 | 샤이어 휴먼 지네틱 테라피즈 인크. | 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들 |
| JP6073783B2 (ja) | 2010-06-25 | 2017-02-01 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
| HRP20191923T1 (hr) | 2010-06-25 | 2020-01-10 | Shire Human Genetic Therapies, Inc. | Postupci i sastavi za isporuku arilsulfataze a u cns |
| JP2012062312A (ja) | 2010-08-19 | 2012-03-29 | Yoshikatsu Eto | ハンター症候群の治療剤 |
| US8580922B2 (en) * | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| MA40460A (fr) | 2014-08-11 | 2016-02-18 | Shire Human Genetic Therapies | Ciblage lysosomial et utilisation correspondante |
| EP3185889B1 (en) | 2014-08-11 | 2020-07-15 | Shire Human Genetic Therapies, Inc. | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes |
| WO2016065319A1 (en) | 2014-10-24 | 2016-04-28 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting of enzymes, and uses thereof |
| US9673835B1 (en) | 2015-12-04 | 2017-06-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Pipelined SAR with TDC converter |
-
2011
- 2011-06-25 PT PT161791504T patent/PT3103469T/pt unknown
- 2011-06-25 DK DK19192679.9T patent/DK3626258T3/da active
- 2011-06-25 PE PE2012002479A patent/PE20130637A1/es not_active Application Discontinuation
- 2011-06-25 HU HUE19192508A patent/HUE056884T2/hu unknown
- 2011-06-25 PT PT191926799T patent/PT3626258T/pt unknown
- 2011-06-25 ES ES19192679T patent/ES2895655T3/es active Active
- 2011-06-25 NZ NZ702803A patent/NZ702803A/en unknown
- 2011-06-25 HU HUE16179150A patent/HUE052944T2/hu unknown
- 2011-06-25 PT PT117990358T patent/PT2588130T/pt unknown
- 2011-06-25 LT LTEP19192679.9T patent/LT3626258T/lt unknown
- 2011-06-25 CN CN201510172262.0A patent/CN104857504A/zh active Pending
- 2011-06-25 HR HRP20211520TT patent/HRP20211520T1/hr unknown
- 2011-06-25 ES ES16179150T patent/ES2858726T3/es active Active
- 2011-06-25 PE PE2012002476A patent/PE20130589A1/es not_active Application Discontinuation
- 2011-06-25 DK DK16179150.4T patent/DK3103469T3/da active
- 2011-06-25 CA CA3171308A patent/CA3171308A1/en active Pending
- 2011-06-25 PE PE2012002474A patent/PE20130578A1/es not_active Application Discontinuation
- 2011-06-25 RS RS20210291A patent/RS61683B1/sr unknown
- 2011-06-25 HU HUE11799036A patent/HUE046856T2/hu unknown
- 2011-06-25 PL PL11799035T patent/PL2588130T3/pl unknown
- 2011-06-25 PT PT117990374T patent/PT2585104T/pt unknown
- 2011-06-25 LT LTEP19192508.0T patent/LT3626257T/lt unknown
- 2011-06-25 PE PE2012002498A patent/PE20130648A1/es not_active Application Discontinuation
- 2011-06-25 CN CN201510512218.XA patent/CN105233277B/zh active Active
- 2011-06-25 BR BR112012033214-7A patent/BR112012033214B1/pt active IP Right Grant
- 2011-06-25 MX MX2013000321A patent/MX354776B/es active IP Right Grant
- 2011-06-25 UA UAA201507529A patent/UA125743C2/uk unknown
- 2011-06-25 CN CN201610086722.2A patent/CN105664142A/zh active Pending
- 2011-06-25 PE PE2017000503A patent/PE20170938A1/es unknown
- 2011-06-25 RU RU2017125281A patent/RU2761342C2/ru active
- 2011-06-25 UA UAA201507721A patent/UA129740C2/uk unknown
- 2011-06-25 SI SI201131959T patent/SI3103469T1/sl unknown
- 2011-06-25 PE PE2012002475A patent/PE20130579A1/es active IP Right Grant
- 2011-06-25 ES ES19192508T patent/ES2896060T3/es active Active
- 2011-06-25 PT PT191925080T patent/PT3626257T/pt unknown
- 2011-06-25 HR HRP20211660TT patent/HRP20211660T1/hr unknown
- 2011-06-25 UA UAA201507719A patent/UA125060C2/uk unknown
- 2011-06-25 CN CN201610569581.XA patent/CN106139133B/zh active Active
- 2011-06-25 RS RS20211191A patent/RS62520B1/sr unknown
- 2011-06-25 RS RS20211359A patent/RS62620B1/sr unknown
- 2011-06-25 HU HUE19192679A patent/HUE055963T2/hu unknown
- 2011-06-25 DK DK19192508.0T patent/DK3626257T3/da active
- 2011-06-25 PE PE2017001612A patent/PE20180130A1/es unknown
- 2011-06-25 HU HUE11799037A patent/HUE046409T2/hu unknown
- 2011-06-25 PE PE2018000183A patent/PE20180801A1/es unknown
- 2011-06-25 SI SI201132007T patent/SI3626258T1/sl unknown
- 2011-06-25 SI SI201132014T patent/SI3626257T1/sl unknown
- 2011-06-25 HU HUE11799035A patent/HUE031036T2/en unknown
- 2011-06-25 NZ NZ702800A patent/NZ702800A/en not_active IP Right Cessation
- 2011-06-25 PT PT117990366T patent/PT2593131T/pt unknown
- 2011-06-25 LT LTEP16179150.4T patent/LT3103469T/lt unknown
- 2011-06-27 AR ARP110102246A patent/AR082025A1/es not_active Application Discontinuation
- 2011-06-27 TW TW106127273A patent/TWI698252B/zh active
- 2011-06-27 AR ARP110102244A patent/AR081680A1/es unknown
- 2011-06-27 TW TW106135183A patent/TWI669128B/zh active
- 2011-06-27 TW TW100122529A patent/TW201212936A/zh unknown
- 2011-06-27 TW TW105115109A patent/TW201701899A/zh unknown
- 2011-06-27 TW TW100122534A patent/TWI602573B/zh active
- 2011-06-27 AR ARP110102242A patent/AR081678A1/es not_active Application Discontinuation
- 2011-06-27 AR ARP110102243A patent/AR081679A1/es unknown
- 2011-06-27 TW TW113122692A patent/TW202506172A/zh unknown
- 2011-06-27 AR ARP110102241A patent/AR081677A1/es not_active Application Discontinuation
- 2011-06-27 TW TW106108970A patent/TWI609694B/zh active
- 2011-06-27 AR ARP110102245A patent/AR081681A1/es unknown
- 2011-06-27 TW TW109118555A patent/TWI790444B/zh active
- 2011-06-27 TW TW112102995A patent/TWI876260B/zh active
-
2012
- 2012-12-21 CL CL2012003656A patent/CL2012003656A1/es unknown
- 2012-12-21 CL CL2012003655A patent/CL2012003655A1/es unknown
- 2012-12-21 CL CL2012003654A patent/CL2012003654A1/es unknown
- 2012-12-21 CL CL2012003657A patent/CL2012003657A1/es unknown
-
2013
- 2013-05-10 US US13/892,076 patent/US9814764B2/en active Active
- 2013-08-23 US US13/974,457 patent/US9220677B2/en active Active
-
2015
- 2015-11-11 US US14/938,824 patent/US20160158324A1/en not_active Abandoned
- 2015-12-03 JP JP2015236539A patent/JP6250616B2/ja active Active
- 2015-12-17 JP JP2015246589A patent/JP2016094451A/ja active Pending
- 2015-12-17 JP JP2015246244A patent/JP6285409B2/ja active Active
- 2015-12-17 JP JP2015246258A patent/JP2016040335A/ja not_active Withdrawn
- 2015-12-18 JP JP2015246952A patent/JP6346162B2/ja active Active
-
2016
- 2016-02-04 US US15/016,141 patent/US10456454B2/en active Active
- 2016-02-25 HK HK16102145.2A patent/HK1214149A1/zh unknown
- 2016-03-22 US US15/077,046 patent/US20170042977A1/en not_active Abandoned
- 2016-10-27 SM SM201600385T patent/SMT201600385B/it unknown
- 2016-12-07 CL CL2016003159A patent/CL2016003159A1/es unknown
-
2017
- 2017-08-23 US US15/684,568 patent/US10646554B2/en active Active
- 2017-09-15 JP JP2017177784A patent/JP6466538B2/ja active Active
- 2017-09-26 US US15/715,748 patent/US11065307B2/en active Active
- 2017-10-03 CL CL2017002488A patent/CL2017002488A1/es unknown
- 2017-10-04 JP JP2017194508A patent/JP6522073B2/ja active Active
- 2017-10-04 JP JP2017194348A patent/JP6522072B2/ja active Active
-
2018
- 2018-07-16 US US16/036,584 patent/US11065308B2/en active Active
- 2018-10-11 JP JP2018192589A patent/JP6797876B2/ja active Active
- 2018-12-03 JP JP2018226358A patent/JP6898909B2/ja active Active
- 2018-12-04 JP JP2018227369A patent/JP6938456B2/ja active Active
-
2019
- 2019-07-18 US US16/515,568 patent/US11260112B2/en active Active
- 2019-09-17 US US16/573,557 patent/US11471516B2/en active Active
-
2020
- 2020-01-07 JP JP2020000930A patent/JP2020079244A/ja not_active Withdrawn
- 2020-02-14 JP JP2020023620A patent/JP2020079297A/ja active Pending
- 2020-02-17 JP JP2020024183A patent/JP2020079298A/ja active Pending
- 2020-02-26 CL CL2020000468A patent/CL2020000468A1/es unknown
- 2020-03-24 US US16/828,731 patent/US12168041B2/en active Active
-
2021
- 2021-02-23 HR HRP20210298TT patent/HRP20210298T1/hr unknown
- 2021-06-17 US US17/350,860 patent/US12161702B2/en active Active
- 2021-07-13 JP JP2021115560A patent/JP7448507B2/ja active Active
- 2021-07-13 JP JP2021115564A patent/JP7087175B2/ja active Active
- 2021-08-18 JP JP2021133184A patent/JP7591476B2/ja active Active
- 2021-12-03 JP JP2021196898A patent/JP7359827B2/ja active Active
-
2022
- 2022-01-18 US US17/578,119 patent/US12121569B2/en active Active
- 2022-08-16 US US17/820,155 patent/US12409210B2/en active Active
-
2023
- 2023-02-02 JP JP2023014814A patent/JP7543459B2/ja active Active
- 2023-02-20 JP JP2023024170A patent/JP2023062114A/ja active Pending
- 2023-05-11 JP JP2023078673A patent/JP2023099216A/ja active Pending
-
2024
- 2024-04-23 JP JP2024069806A patent/JP2024097029A/ja not_active Ceased
- 2024-09-19 US US18/890,181 patent/US20250121040A1/en active Pending
- 2024-10-29 US US18/930,737 patent/US20250161417A1/en active Pending
-
2025
- 2025-08-15 US US19/301,198 patent/US20250375506A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016094451A5 (https=) | ||
| JP2013542913A5 (https=) | ||
| US20200270590A1 (en) | P97-ids fusion proteins | |
| JP2016040335A5 (https=) | ||
| US9192649B2 (en) | Annexin and its use to treat inflammatory disorders | |
| CN104039811B (zh) | 具有改善的细胞渗透性的新的大分子转导结构域的研发及其使用方法 | |
| US20200048324A1 (en) | Tissue-specific wnt signal enhancing molecules and uses thereof | |
| JP2017529326A5 (https=) | ||
| JP6794409B2 (ja) | シータデフェンシンによる炎症性プロテアーゼの遮断 | |
| JP2018522563A5 (https=) | ||
| JP2019519528A5 (https=) | ||
| CN114341195B (zh) | 治疗性融合蛋白 | |
| WO2011036442A3 (en) | Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders | |
| JP2011504366A5 (https=) | ||
| EA201200515A1 (ru) | Полипептиды и их применение | |
| US20170029798A1 (en) | Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD) | |
| JP2011528222A5 (https=) | ||
| US12428445B2 (en) | Mini-nucleosome core proteins and use in nucleic acid delivery | |
| RU2016152151A (ru) | Препарат, содержащий фактор viii и пептиды фактора фон виллебранда | |
| CN106279439A (zh) | 一种含有穿膜肽的寡肽‑1融合蛋白及其制备方法 | |
| CA3205570A1 (en) | Fusion molecule having non-inflammatory phagocytosis inducing activity | |
| JP2020037538A (ja) | アンジオテンシン変換酵素２活性を有する原核微生物由来ポリペプチドの医薬用途 | |
| JP2021534206A (ja) | Ｇｓｘ１を使用した脊髄損傷（ｓｃｉ）および脳損傷の処置 | |
| WO2013052814A8 (en) | E1 enzyme mutants and uses thereof | |
| CN115427428A (zh) | 新的细胞穿透肽及其用途 |